{
  "pmcid": "8675044",
  "sha256": "0218192c14d3e8034a573bd4545cf239581b1905a82599b8b3845903b83c2218",
  "timestamp_utc": "2025-11-09T22:59:14.436457+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.521404255319151,
    "reading_ease": 27.61366666666669,
    "word_count": 188
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of DFN-15 for Acute Pain Management Post-Dental Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "In a single-center, randomized, double-blind, placebo-controlled, dose-ranging trial, 120 adults undergoing bilateral mandibular third molar extraction were randomized 1:1:1:1"
      },
      "Participants": {
        "score": 2,
        "evidence": "120 adults undergoing bilateral mandibular third molar extraction"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized 1:1:1:1 to receive a single dose of placebo or DFN-15 (62.5, 125, or 250 mg)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluated the efficacy and safety of DFN-15, a liquid celecoxib formulation, for acute pain post-dental surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the summed pain intensity difference (SPID) over 6 hours post-dose."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included participants, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "120 adults undergoing bilateral mandibular third molar extraction were randomized 1:1:1:1"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "All 120 participants were analyzed using a modified intent-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "DFN-15 significantly reduced SPID6 compared to placebo (least square mean differences: −756.6, −1120.7, −1355.1; P < 0.0001 for all doses)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between DFN-15 and placebo groups, with no dose-related trends."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT03554772"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Dr. Reddy's Laboratories"
      }
    },
    "total_score": 25,
    "max_score": 25
  }
}